Vectibix (panitumumab) - Important Safety Information from Amgen as approved by the Irish Medicines Board
26 April 2010
Important Safety Information communication from Amgen on serious hypersensitivity including anaphylaxis and angiodema.
Important Safety Information - Vectibix (panitumumab)